N-(6-methoxy-1,3-benzothiazol-2-yl)-4-methylbenzamide | 91506-70-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: N-(6-methoxy-1,3-benzothiazol-2-yl)-4-methylbenzamide
• CAS: 91506-70-6
• 化学式: C₁₆H₁₄N₂O₂S
• 分子量: 298.365
• InChiKey: IZAJRNCGGRELRJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  79.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(6-methoxy-1,3-benzothiazol-2-yl)-4-methylbenzamide 在 sodium azide 、 五氯化磷 、 sodium acetate 作用下， 生成 6-Methoxy-2-(5-p-tolyl-tetrazol-1-yl)-benzothiazole
  参考文献：
  名称：

  Kamala, K.; Rao, P. Jayaprasad; Reddy, K. Kondal, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1983, vol. 22, # 12, p. 1194 - 1196

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基-6-甲氧基苯并噻唑 、 对甲基苯甲酰氯 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 N-(6-methoxy-1,3-benzothiazol-2-yl)-4-methylbenzamide
  参考文献：
  名称：

  Synthesis of amide and urea derivatives of benzothiazole as Raf-1 inhibitor

  摘要：

  A series of amide and urea derivatives of benzothiazole have been synthesized and evaluated for their antiproliferative profile in human SK-Hep-1 (liver), MDA-MB-231 (breast), and NUGC-3 (gastric) cell lines. Among them, compounds 1-2, 16-18, 23, and 25-26 had potent to moderate inhibitory activities. Further these compounds were investigated for their ability to inhibit Raf-1 activity. (c) 2007 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2007.10.008

文献信息

• [EN] BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA<br/>[FR] AMIDES DE BENZOTHIAZOLE POUR LA DÉTECTION DE BÊTA-AMYLOÏDE
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2010066357A1

  公开（公告）日：2010-06-17

  This invention relates to compounds of formula I (benzothiazoles) suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging.

  这项发明涉及适用于标记或已经用18F标记的化合物I（苯并噻唑），制备这种化合物的方法，包含这种化合物的组合物，包含这种化合物或组合物的试剂盒以及这种化合物、组合物或试剂盒用于诊断成像的用途。
• [EN] TRIARYL-SULPHONIUM COMPOUNDS, KIT AND METHODS FOR LABELING POSITRON EMITTING ISOTOPES<br/>[FR] COMPOSÉS DE TRIARYL-SULPHONIUM, KIT ET PROCÉDÉ POUR ÉTIQUETER DES ISOTOPES ÉMETTANT DES POSITRONS
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2010066380A1

  公开（公告）日：2010-06-17

  This invention relates to novel compounds suitable for labeling by positron emitting isotopes, such as 18F, 11C, 13N and 15O, through appropriate labeling reagents, such as 18F reagents and methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

  本发明涉及一种适合通过适当的标记试剂（如18F试剂）标记正电子发射同位素（如18F、11C、13N和15O）的新化合物，以及制备这种化合物的方法，包括这种化合物的组合物，包含这种化合物或组合物的试剂盒以及这种化合物、组合物或试剂盒在正电子发射断层扫描（PET）中的诊断成像用途。
• [EN] BENZOTHIAZOLE AND THIAZOLE'5,5-B!PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS<br/>[FR] COMPOSITIONS DE BENZOTHIAZOLE ET DE THIAZOLE'5,5-B!PYRIDINE ET LEUR UTILISATION COMME INHIBITEURS DE L'UBIQUITINE LIGASE
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2005037845A1

  公开（公告）日：2005-04-28

  This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also comprises the use of the compounds and pharmaceutical compositions of the invention for the treatment of conditions that require inhibition of ubiquitination. Furthermore, the invention comprises methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a pharmaceutical composition according to the invention.

  这项发明描述了化合物和制药组合物，作为泛素代理抑制剂。该发明的化合物和制药组合物作为抑制泛素化参与的生物化学途径的抑制剂是有用的。该发明还包括使用该发明的化合物和制药组合物治疗需要抑制泛素化的情况。此外，该发明还包括通过使用该发明的制药组合物接触需要抑制泛素化的细胞来抑制细胞内泛素化的方法。
• Benzothiazole compositions and their use as ubiquitin ligase inhibitors
  申请人：Ramesh V. Usha

  公开号：US20050130974A1

  公开（公告）日：2005-06-16

  This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also comprises the use of the compounds and pharmaceutical compositions of the invention for the treatment of conditions that require inhibition of ubiquitination. Furthermore, the invention comprises methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a pharmaceutical composition according to the invention.

  本发明描述了化合物和药物组合物，可用作泛素代理抑制剂。本发明的化合物和药物组合物可用作生物体中涉及泛素化的生化途径的抑制剂。本发明还包括使用本发明的化合物和药物组合物治疗需要抑制泛素化的疾病的方法。此外，本发明还包括通过将本发明的药物组合物接触到需要抑制泛素化的细胞中来抑制细胞泛素化的方法。
• Benzothniazole compositions and their use as ubiquition ligation inhibitors
  申请人：Ramesh V. Usha

  公开号：US20080039629A1

  公开（公告）日：2008-02-14

  This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also comprises the use of the compounds and pharmaceutical compositions of the invention for the treatment of conditions that require inhibition of ubiquitination. Furthermore, the invention comprises methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a pharmaceutical composition according to the invention.

  本发明描述了化合物和药物组合物，作为泛素剂抑制剂。本发明的化合物和药物组合物可用作生物体中泛素化参与的生化途径的抑制剂。本发明还包括使用本发明的化合物和药物组合物治疗需要抑制泛素化的疾病的方法。此外，本发明还包括抑制细胞中泛素化的方法，其中包括将需要抑制泛素化的细胞与本发明的药物组合物接触。